Form 4: Fate Therapeutics CEO Awarded 1.3 Million Stock Options
SEC Form 4 Filing
Fate Therapeutics' CEO, Bahram Valamehr, was granted 1.3 million stock options with a vesting schedule over three years.
Summary
- Bahram Valamehr, the President and CEO of Fate Therapeutics, was granted 1,300,000 stock options.
- The options have an exercise price of $1.25 per share.
- The options vest in 36 equal monthly installments starting January 1, 2025, and will be fully vested by January 1, 2028.
- The vesting is contingent upon Mr. Valamehr's continued service with the company.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The grant of stock options aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the options is dependent on the future performance of the company's stock price.
- If the CEO leaves the company before the options are fully vested, they may be forfeited.
Future Outlook
The stock options will vest over the next three years, contingent on the CEO's continued service.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for executive compensation in the biotech industry.
- The vesting schedule of 36 months is typical for such grants, encouraging long-term commitment.
- The exercise price of $1.25 is a common practice, often set at or near the market price at the time of the grant.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase the company's value.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/16/2025 | Date of the stock option grant. |
| 01/01/2025 | Start date for the monthly vesting of the stock options. |
| 01/01/2028 | Date when all stock options will be fully vested. |
| 01/15/2035 | Expiration date of the stock options. |
Keywords
stock options, executive compensation, insider trading, Fate Therapeutics, Bahram Valamehr, equity
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.